Examination about safety and the effectiveness when we switched from a GnRH antagonist to a GnRH agonist at the time of prostate cancer hormonal therapy introductio
Not Applicable
- Conditions
- Prostate Cancer
- Registration Number
- JPRN-UMIN000011379
- Lead Sponsor
- Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Male
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1.The patient who has the condition by metastasis 2.Gleason Score8over 3.Prostate volume 50cc over 4.The patient who judged that a doctor in charge was unsuitable
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in LH and testosterone level after switch the GnRH agonist
- Secondary Outcome Measures
Name Time Method Changes in LH, testosterone, PSA. FSH level after administration of the GnRH antagonist